Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium-225-macropa-polyethylene glycol-4-YS5-monomethyl auristatin E
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Administration
- Parenteral
01
Overview
**Actinium-225-macropa-polyethylene glycol-4-YS5-monomethyl auristatin E** is an investigational CD46-directed dual-payload radioimmunoconjugate developed by University of California researchers for prostate cancer and multiple myeloma. The single covalent construct incorporates the CD46-targeting YS5 antibody, a Macropa-PEG4 chelator complexed with the alpha-emitting radionuclide actinium-225, and the microtubule-disrupting cytotoxic payload monomethyl auristatin E delivered through an mc-vc-pab linker. CD46-mediated tumor targeting enables localized alpha-particle irradiation and intracellular delivery of monomethyl auristatin E, producing DNA damage and mitotic disruption. In preclinical prostate cancer models, the dual-labeled construct produced durable tumor regression and improved survival relative to either CD46-targeted alpha therapy or the YS5-monomethyl auristatin E antibody-drug conjugate alone.
- Other names
- 225Ac-Macropa-PEG4-YS5-MMAE[225Ac]-Macropa-PEG4-YS5-MMAE[225Ac]Macropa-PEG4-YS5-MMAEactinium-225-macropa-polyethylene glycol-4-YS5-monomethyl auristatin Eactinium225-macropa-polyethylene glycol-4-YS5-monomethyl auristatin Eactinium 225-macropa-polyethylene glycol-4-YS5-monomethyl auristatin ER-ADC
02
Targets
CD46 (CD46 Molecule)
Beyond the preview
Go deeper on actinium-225-macropa-polyethylene glycol-4-YS5-monomethyl auristatin E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium-225-macropa-polyethylene glycol-4-YS5-monomethyl auristatin E.